Immunosuppression and the CD28 receptor
- 1 August 1994
- journal article
- Published by Springer Nature in Perspectives in Drug Discovery and Design
- Vol. 2 (1) , 221-231
- https://doi.org/10.1007/bf02171745
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Identification of an Alternatively Spliced Form of the Murine Homolog of B7Biochemical and Biophysical Research Communications, 1994
- A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7.The Journal of Experimental Medicine, 1993
- The Role of the CD28 Receptor During T Cell Responses to AntigenAnnual Review of Immunology, 1993
- B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cellsin vitroEuropean Journal of Immunology, 1993
- Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.The Journal of Experimental Medicine, 1992
- Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation MoleculeScience, 1992
- Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lgScience, 1992
- CTLA-4 is a second receptor for the B cell activation antigen B7.The Journal of Experimental Medicine, 1991
- Role of the CD28 receptor in T-cell activationImmunology Today, 1990
- Immunobiology of Tissue Transplantation: A Return to the Passenger Leukocyte ConceptAnnual Review of Immunology, 1983